Literature DB >> 200863

Cytomegalovirus complement fixation antibody in Guillain-Barré syndrome.

P Dowling, J Menonna, S Cook.   

Abstract

Cytomegalovirus, measles, and adenovirus antibodies were measured in the sera of 92 Guillain-Barré patients and 120 controls. Thirty patients (33 percent) had markedly elevated levels of complement-fixing antibody to cytomegalovirus and in 21, a fourfold or more alteration in titer was demonstrated. Diagnostic falls in titer were seen in most instances and no significant elevation to the other viral agents was found. The serologic findings reported here suggest that cytomegalovirus may be a common agent involved in the pathogenesis of the Guillain-Barré syndrome.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 200863     DOI: 10.1212/wnl.27.12.1153

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  4 in total

1.  Detection of virus-specific IgA antibodies in serum of kidney transplant patients with recurrent cytomegalovirus infection by enzymeimmuno and radioimmunoassay techniques.

Authors:  I Sarov; E Levy; M Aymard; Y Chardonnet; S Bosshard; J P Revillard; M Friedman; E Nord; M Greiff; H Haikin
Journal:  Clin Exp Immunol       Date:  1982-05       Impact factor: 4.330

2.  Cytomegalovirus isolation from a chimpanzee with acute demyelinating disease after inoculation of multiple sclerosis brain cells.

Authors:  Z Wroblewska; D Gilden; M Devlin; E S Huang; L B Rorke; T Hamada; T Furukawa; L Cummins; S Kalter; H Koprowski
Journal:  Infect Immun       Date:  1979-09       Impact factor: 3.441

3.  Growth of murine cytomegalovirus in murine and heterologous brain cell cultures. Brief report.

Authors:  G Barabas; Z Wroblewska; D H Gilden
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

4.  Determination of specific IGA antibodies to varicella zoster virus by immunoperoxidase assay.

Authors:  H Haikin; I Sarov
Journal:  J Clin Pathol       Date:  1982-06       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.